Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19

Benjamin Faucher, Rania Assab, Jonathan Roux, Daniel Levy-Bruhl, Cécile Tran Kiem, Simon Cauchemez, Laura Zanetti, Vittoria Colizza, Pierre-Yves Boëlle and Chiara Poletto ()
Additional contact information
Benjamin Faucher: Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique
Rania Assab: Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique
Jonathan Roux: Univ Rennes, EHESP, CNRS, ARENES—UMR 6051
Daniel Levy-Bruhl: Santé Publique France
Cécile Tran Kiem: Université de Paris, UMR2000, CNRS
Simon Cauchemez: Université de Paris, UMR2000, CNRS
Laura Zanetti: Haute Autorité de Santé
Vittoria Colizza: Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique
Pierre-Yves Boëlle: Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique
Chiara Poletto: Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique

Nature Communications, 2022, vol. 13, issue 1, 1-11

Abstract: Abstract With vaccination against COVID-19 stalled in some countries, increasing vaccine accessibility and distribution could help keep transmission under control. Here, we study the impact of reactive vaccination targeting schools and workplaces where cases are detected, with an agent-based model accounting for COVID-19 natural history, vaccine characteristics, demographics, behavioural changes and social distancing. In most scenarios, reactive vaccination leads to a higher reduction in cases compared with non-reactive strategies using the same number of doses. The reactive strategy could however be less effective than a moderate/high pace mass vaccination program if initial vaccination coverage is high or disease incidence is low, because few people would be vaccinated around each case. In case of flare-ups, reactive vaccination could better mitigate spread if it is implemented quickly, is supported by enhanced test-trace-isolate and triggers an increased vaccine uptake. These results provide key information to plan an adaptive vaccination rollout.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-29015-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29015-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-29015-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().